Objective assessment of medical treatment of endometriosis with gestrinone (R2323)

Jean-Claude Emperaire, A Audebert
In: Diagnosis and Management of Tubo-Uterine Factors in Infertility · 1984 · pp. 111–115 · doi:10.1007/978-94-011-7621-7_22 · W100598578
book-chapter OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-16 ⓘ

Gestrinone (R2323), a synthetic steroid with antioestrogenic and antiprogesterone activity, was investigated for the medical treatment of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-16 · read from full text ⓘ

This chapter reviews the medical treatment of endometriosis using gestrinone (R2323), a trienic steroid described as having antioestrogenic activity and true antiprogesterone activity via competitive binding to progesterone receptors. It frames gestrinone’s pharmacologic rationale by comparing it with related hormonal effects and citing prior clinical evaluations of R2323, including reports on ovarian function and metabolic parameters during weekly oral administration. The chapter’s main emphasis is on “objective assessment” of medical therapy, but the excerpt provided does not include specific outcome data or an explicit stated limitation beyond the reliance on prior studies. This paper is centrally about endometriosis — it specifically evaluates medical treatment of endometriosis with gestrinone (R2323).

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,874 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Gestrinone (R2323) is a trienic steroid with an ethyl group in position 13, close to norgestrienone which has a methyl group in the same position, and which is marketed in France as a contraceptive pill in association with ethinyl oestradiol (Figure 1). The compound shows an antioestrogenic activity, and a true antiprogesterone activity by competitive binding to the progesterone receptors1,2. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

References

Azadian-Boulanger, G., Secchi, J. and Sakiz, E. (1971). Biological study of the anti-progesterone effect of R2323. In Proceedings of the 7th World Congress of Fertility and Sterility. p. 129. ( Amsterdam: Excepta Medica ) Sakiz, E. and Azadian-Boulanger, G. (1970). R2323. An original contraceptive compound. In Proceedings of the Third International Congress on Hormonal Steroids. p. 865. (Amsterdam: Excerpta Medica ) Coutinho, E. M. (1982). Treatment of endometriosis with gestrinone (R2323), a synthetic anti-estrogen, antiprogesterone. Am. J. Obstet. Gynecol., 144, 895 American Fertility Society (1979). Classification of endometriosis. Fertil. Steril., 32, 633 Dmowski, W. P. and Cohen, M. R. (1978). Antigonadotropin (danazol) in the treatment of endometriosis. Am. J. Obstet. Gynecol., 130, 41 Mora, G., Faundes, A. and Pastore, U. (1974). Clinical evaluation of an oral progestin contraceptive, R2323, 5mg, administered at weekly intervals. Contraception, 10, 145 Victor, A. and Johansson, E. D. B. (1975). The effect of weekly administration of an oral progestogen - R2323 - on the ovarian function. Contraception, 12, 89 Spellacy, W.N., Mahan, C. S., Buhi, W.C., Dumbaugh, V.A. and Birk, S.A. (1978). Blood glucose, insulin, cholesterol and triglyceride levels in women treated for six months with the weekly oral contraceptive R2323. Contraception, 18, 121 Audebert, A. J. M., Bernard, I. and Emperaire, J. C. (1977). Treatment of endometriosis with danazol. Gynécologie, 1, 29 Editor information Editors and Affiliations Rights and permissions Copyright information © 1984 MTP Press Limited About this chapter Cite this chapter Emperaire, J.C., Audebert, A.J.M. (1984). Objective assessment of medical treatment of endometriosis with gestrinone (R2323). In: Harrison, R.F., Bonnar, J., Thompson, W. (eds) Diagnosis and Management of Tubo-Uterine Factors in Infertility. Studies in Fertility and Sterility, vol 4. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-7621-7_22 Download citation DOI: https://doi.org/10.1007/978-94-011-7621-7_22 Publisher Name: Springer, Dordrecht Print ISBN: 978-94-011-7623-1 Online ISBN: 978-94-011-7621-7 eBook Packages: Springer Book Archive

Keywords

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (10)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK